PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats
Journal of Cardiovascular Translational Research · 2024
DOI: 10.1007/s12265-024-10499-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Translational Research, 2024. Verfasst von Ningzhi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Hauptthemen laut MEDLINE: PPAR gamma, Hypertension, Rosiglitazone, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The increased incidence of hypertension associated with obstructive sleep apnea (OSA) presents significant physical, psychological, and economic challenges. Peroxisome proliferator-activated receptor gamma (PPARγ) plays a role in both OSA and hypertension, yet the therapeutic potential of PPARγ agonists and antagonists for OSA-related hypertension remains unexplored. Therefore, we constructed a chronic intermittent hypoxia (CIH)-induced hypertension rat model that mimics the pathogenesis of OSA-related hypertension in humans. The model involved administering PPARγ agonist rosiglitazone (RSG), PPARγ antagonist GW9662, or normal saline, followed by regular monitoring of blood pressure and thoracic aorta analysis using staining and electron microscopy. Intriguingly, our results indicated that both RSG and GW9662 appeared to potently counteract CIH-induced hypertension. In silico study suggested that GW9662's antihypertensive effect might mediated through angiotensin II receptor type 1 (AGTR1). Our findings provide insights into the mechanisms of OSA-related hypertension and propose novel therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
- Department of Cardiology, Shanghai Changning Tianshan Traditional Chinese Medicine Hospital, Shanghai, China.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. jbge@zs-hospital.sh.cn.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. zhaoq_cui@163.com.
ORCID-Profile: Zhaoqiang Cui
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, N., Wei, F., Ning, S., Hu, J., Shi, H., Yao, Z., Tang, M., Zhang, Y., Gong, J., Ge, J., & Cui, Z. (2024). PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats. Journal of Cardiovascular Translational Research. https://doi.org/10.1007/s12265-024-10499-6
Vancouver
Zhang N, Wei F, Ning S, Hu J, Shi H, Yao Z, et al. PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats. Journal of Cardiovascular Translational Research. 2024. doi:10.1007/s12265-024-10499-6
BibTeX
@article{Zhang2024,
author = {Zhang, Ningzhi and Wei, Feng and Ning, Sisi and Hu, Jialu and Shi, Hongtao and Yao, Zhifeng and Tang, Minna and Zhang, Yongqiao and Gong, Jiaxin and Ge, Junbo and Cui, Zhaoqiang},
title = {PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats},
journal = {Journal of Cardiovascular Translational Research},
year = {2024},
doi = {10.1007/s12265-024-10499-6}
}
EUVIMED